The activation of GPR143 also triggers a reduction in the vascular endothelial growth factor (VEGF); it has therefore been proposed as a potential treatment for age-related macular degeneration (AMD) [42,43]. The gene discussed is VEGFA; the disease is age-related macular degeneration.